COX-2 mediated induction of endothelium-independent contraction to bradykinin in endotoxin-treated porcine coronary artery. 2014

Amar S More, and Hye Min Kim, and Ru Zhao, and Gilson Khang, and Tobias Hildebrandt, and Christian Bernlöhr, and Henri Doods, and Dongwon Lee, and Seung Hee Lee, and Paul M Vanhoutte, and Dongmei Wu
*WCU program, Department of BIN Fusion Technology, Chonbuk National University, Chonju, Korea; †CNS Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; and ‡Department of Pharmacology, University of Hong Kong, Hong Kong, China.

This study examined the vascular effects of bradykinin in health and vascular inflammation comparing responses of isolated pig coronary arteries in the absence and presence of endotoxins. Bradykinin induced contractions in lipopolysaccharide-treated, but not untreated, arterial rings without endothelium. The B2-receptor antagonist HOE140, but not the B1-receptor inhibitor SSR240612, blocked these endothelium-independent contractions in response to bradykinin. The bradykinin-induced contractions were blocked by indomethacin, celecoxib, and terbogrel but not valeryl salicylate, AH6809, AL 8810, or RO1138452. They were attenuated by N-(p-amylcinnamoyl) anthranilic acid, and by diethyldithiocarbamate plus tiron but not by L-NAME. Quantitative reverse-transcription polymerase chain reaction revealed significant upregulations of messenger RNA expressions of B1 receptors, COX-2, and thromboxane A synthase 1 (TBXAS1) following lipopolysaccharide incubation but not of B2 receptors or COX-1. The present data demonstrate that bradykinin induces contractions mediated by the COX-2 pathway in endotoxin-treated pig coronary arteries. These results support differential roles of bradykinin in health and disease.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D001920 Bradykinin A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter. Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg,Bradykinin Acetate, (9-D-Arg)-Isomer,Bradykinin Diacetate,Bradykinin Hydrochloride,Bradykinin Triacetate,Bradykinin, (1-D-Arg)-Isomer,Bradykinin, (2-D-Pro)-Isomer,Bradykinin, (2-D-Pro-3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (2-D-Pro-7-D-Pro)-Isomer,Bradykinin, (3-D-Pro)-Isomer,Bradykinin, (3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (5-D-Phe)-Isomer,Bradykinin, (5-D-Phe-8-D-Phe)-Isomer,Bradykinin, (6-D-Ser)-Isomer,Bradykinin, (7-D-Pro)-Isomer,Bradykinin, (8-D-Phe)-Isomer,Bradykinin, (9-D-Arg)-Isomer,Arg Pro Pro Gly Phe Ser Pro Phe Arg
D003331 Coronary Vessels The veins and arteries of the HEART. Coronary Arteries,Sinus Node Artery,Coronary Veins,Arteries, Coronary,Arteries, Sinus Node,Artery, Coronary,Artery, Sinus Node,Coronary Artery,Coronary Vein,Coronary Vessel,Sinus Node Arteries,Vein, Coronary,Veins, Coronary,Vessel, Coronary,Vessels, Coronary
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D004731 Endotoxins Toxins closely associated with the living cytoplasm or cell wall of certain microorganisms, which do not readily diffuse into the culture medium, but are released upon lysis of the cells. Endotoxin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D013552 Swine Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA). Phacochoerus,Pigs,Suidae,Warthogs,Wart Hogs,Hog, Wart,Hogs, Wart,Wart Hog

Related Publications

Amar S More, and Hye Min Kim, and Ru Zhao, and Gilson Khang, and Tobias Hildebrandt, and Christian Bernlöhr, and Henri Doods, and Dongwon Lee, and Seung Hee Lee, and Paul M Vanhoutte, and Dongmei Wu
June 2009, Journal of veterinary pharmacology and therapeutics,
Amar S More, and Hye Min Kim, and Ru Zhao, and Gilson Khang, and Tobias Hildebrandt, and Christian Bernlöhr, and Henri Doods, and Dongwon Lee, and Seung Hee Lee, and Paul M Vanhoutte, and Dongmei Wu
January 2007, European journal of pharmacology,
Amar S More, and Hye Min Kim, and Ru Zhao, and Gilson Khang, and Tobias Hildebrandt, and Christian Bernlöhr, and Henri Doods, and Dongwon Lee, and Seung Hee Lee, and Paul M Vanhoutte, and Dongmei Wu
July 1990, The Journal of pharmacology and experimental therapeutics,
Amar S More, and Hye Min Kim, and Ru Zhao, and Gilson Khang, and Tobias Hildebrandt, and Christian Bernlöhr, and Henri Doods, and Dongwon Lee, and Seung Hee Lee, and Paul M Vanhoutte, and Dongmei Wu
May 1989, Biochemical and biophysical research communications,
Amar S More, and Hye Min Kim, and Ru Zhao, and Gilson Khang, and Tobias Hildebrandt, and Christian Bernlöhr, and Henri Doods, and Dongwon Lee, and Seung Hee Lee, and Paul M Vanhoutte, and Dongmei Wu
January 2016, Stem cells international,
Amar S More, and Hye Min Kim, and Ru Zhao, and Gilson Khang, and Tobias Hildebrandt, and Christian Bernlöhr, and Henri Doods, and Dongwon Lee, and Seung Hee Lee, and Paul M Vanhoutte, and Dongmei Wu
March 2000, British journal of pharmacology,
Amar S More, and Hye Min Kim, and Ru Zhao, and Gilson Khang, and Tobias Hildebrandt, and Christian Bernlöhr, and Henri Doods, and Dongwon Lee, and Seung Hee Lee, and Paul M Vanhoutte, and Dongmei Wu
July 1998, The Journal of pharmacology and experimental therapeutics,
Amar S More, and Hye Min Kim, and Ru Zhao, and Gilson Khang, and Tobias Hildebrandt, and Christian Bernlöhr, and Henri Doods, and Dongwon Lee, and Seung Hee Lee, and Paul M Vanhoutte, and Dongmei Wu
January 2014, Vascular pharmacology,
Amar S More, and Hye Min Kim, and Ru Zhao, and Gilson Khang, and Tobias Hildebrandt, and Christian Bernlöhr, and Henri Doods, and Dongwon Lee, and Seung Hee Lee, and Paul M Vanhoutte, and Dongmei Wu
July 2006, Molecular and cellular biochemistry,
Amar S More, and Hye Min Kim, and Ru Zhao, and Gilson Khang, and Tobias Hildebrandt, and Christian Bernlöhr, and Henri Doods, and Dongwon Lee, and Seung Hee Lee, and Paul M Vanhoutte, and Dongmei Wu
November 2003, European journal of pharmacology,
Copied contents to your clipboard!